Pharmaceutical

Image

Global Iron-Deficiency Anemia Therapy Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Upcoming Report
  • Feb 2023
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Iron-Deficiency Anemia Therapy Market – Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR - % Diagram

Diagram Forecast Period 2022–2030
Diagram Market Size (Base Year) USD 3710.61 Billion
Diagram Market Size (Forecast Year) USD 13208.89 Billion
Diagram CAGR %

Global Iron-Deficiency Anemia Therapy Market, By Therapy (Parenteral Iron Therapy, Oral Iron Therapy), Therapy Areas (Inflammatory Bowel Disease, Renal, Obstetrics, and Gynecology, Congestive Heart Failure (CHF), Oncology, Others) Population (Adults, Pediatric, Geriatric), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.

Iron-Deficiency Anemia Therapy Market Analysis and Size

The market for iron deficiency anemia therapy is expected to expand quickly during the coming years. The World Health Organization estimates that between 1.5 and 1.74 billion individuals worldwide suffer from anemia, with iron deficiency accounting for 50% of all cases. The rising incidence of iron deficiency anemia is anticipated to be favorable for the global market for therapies for the condition.

Data Bridge Market Research analyses that the iron-deficiency anemia therapy market, which is USD 3710.61 million in 2022, is expected to reach USD 13,208.89 million by 2030, at a CAGR of 17.2% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Iron-Deficiency Anemia Therapy Market Scope and Segmentation  

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015 - 2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Therapy (Parenteral Iron Therapy, Oral Iron Therapy), Therapy Areas (Inflammatory Bowel Disease, Renal, Obstetrics and Gynecology, Congestive Heart Failure (CHF), Oncology, Others) Population (Adults, Pediatric, Geriatric), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Fresenius SE & Co. KGaA (Germany), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AbbVie Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Ireland), Lupin (India), ViforPharma Ltd. (Switzerland), AMAG Pharmaceuticals (U.S.), Akebia Therapeutics, INC. (U.S.), CHO-A Pharmaceutical CO., LTD. (South Korea), Orion Corporation (Finland), Pharmacosmos A/S (Denmark), Shield Therapeutics (U.K.), Advanz Pharmaceutical (U.K.), Alkem Labs (India), Zydus Cadila (India), Hikma Pharmaceuticals PLC (U.K.)

Market Opportunities

  • An increase in anemia cases will act as an opportunity
  • Increasing incidence of cancer is a promising opportunity

Market Definition

Iron-deficiency anemia can be treated or prevented with the use of iron-deficiency of foods such as fruits, meat, vegetables, and cereals high in iron. Iron deficiency can be prevented by vitamin C consumption. An inadequate number of healthy red blood cells is a sign of anemia. RBCs give human tissues oxygen. Hemoglobin formation depends on iron, which is present in red blood cells. A low hemoglobin level suggests that the body is not getting enough oxygen. Maintaining a healthy iron level is essential.

Iron-Deficiency Anemia Therapy Market Dynamics

Drivers

• Increasing prevalence of iron deficiency anemia (IDA) will bolster the market growth

Iron deficiency anemia (IDA) is more common than average in developing nations. For instance, a 2017 study by researchers at the Indira Gandhi Institute of Medical Sciences in Bihar, India, found that IDA affected 50% of the adolescent girls polled for the study. 3.3% of them had severe anemia. These startling figures are primarily attributable to inadequate iron intake from regular food sources and blood loss during menstruation and pregnancy. Treatments for iron deficiency anemia may be essential in giving girls and other vulnerable groups the nutrients they need to avoid developing an anemic. Additionally, these treatments can aid in reducing the negative consequences of IDA and improve the health of those affected.

• Growing research and clinical activities will drive the market growth

The popularity of oral iron therapy is predicted to rise, fuelling the segment's expansion, as more studies are coming out in favor of its use as an intravenous treatment alternative in hospital settings. For instance, oral iron supplementation has been regarded as the main treatment for iron deficiency anaemia in children that affects their growth and development, according to the most recent study published by the IRESPUB Journal of Life Sciences in January 2022 and titled "Oral iron formulae for treatment of iron deficiency anemia: a comparative study." But this accelerates the market's expansion.

Opportunities

  • An increase in anemia cases will act as an opportunity

Especially in women and children, iron deficiency anemia is becoming more common due to inadequate dietary iron intake and excessive red blood cell loss. This can cause developmental disorders in developing fetuses in pregnant women and growing children, respectively. According to observations, in 2020, anemia was discovered in roughly 53% of women. According to the National Heart, Lung, and Blood Institute's records, 3 million people in North America are estimated to have anemia. One of the main factors influencing the growth of the iron-deficiency anemia therapy market is the rising prevalence of target diseases such as autoimmune diseases, rheumatoid arthritis, renal problems, liver disorders, cancer, thyroid diseases, and inflammatory bowel diseases.

• Increasing incidence of cancer is a promising opportunity

Iron deficiency anemia is becoming more common among cancer patients. Bone cancer, cervical cancer, blood cancer, colon cancer, and prostate cancer are common cancers that are frequently linked to anemia. Among solid tumors, lung and breast tumors have been identified as having the highest anemic prevalence. Anemia is brought on by abnormal blood cells produced by hematologic malignancies such as lymphoma, leukemia, and multiple myeloma. These diseases impair the immune system. Anemia in cancer patients is also made worse by cancer therapies like chemotherapy and radiation. As a result, the market has additional opportunities.

Restraints/Challenges

  • The serious effects of iron supplements will hamper the market growth

Consuming iron-containing medications has only a few minor negative effects. Digestive issues like nausea, vomiting, stomach aches and constipation are typical side effects, as well as problems with appetite. Along with exhaustion, weakness, shallow or quick breathing, bluish skin, convulsions, pale skin, or fingernails, these medicines can also induce overdose symptoms. Because of this, the market expansion is hindered.

This iron-deficiency anemia therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the iron-deficiency anemia therapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

  • In 2021, Sandoz announced the launch of Ferumoxytol Injection, the first generic high-dose intravenous iron. This medication is used to treat anemia caused by iron deficiency in U.S. patients. IDA in adults with an aversion to oral iron, a poor reaction to oral iron, or chronic renal disease is treatable with ferumoxytol, a generic version of AMAG Pharmaceuticals' Feraheme.
  • In 2022, The Drug Controller General of India granted approval to Zydus' New Drug Application (NDA) for Oxemia. Oxemia is an oral, small-molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) used to treat anemia linked to chronic kidney disease (CKD).

Global Iron-Deficiency Anemia Therapy Market Scope

The iron-deficiency anemia therapy market is segmented on the basis of therapy, therapy areas, population, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Therapy

  • Parenteral Iron Therapy
  • Oral Iron Therapy

Therapy Areas

  • Inflammatory Bowel Disease
  • Renal
  • Obstetrics and Gynecology
  • Congestive Heart Failure (CHF)
  • Oncology
  • Others

Population

  • Adults
  • Pediatric
  • Geriatric

End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Iron-Deficiency Anemia Therapy Market Regional Analysis/Insights

The iron-deficiency anemia therapy market is analysed and market size insights and trends are provided by country, therapy, therapy areas, population, end-users and distribution channel as referenced above.

The countries covered in the iron-deficiency anemia therapy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the iron-deficiency anemia therapy market due of the region's developed healthcare system. Further accelerating the market's growth rate in this region will be the increased emphasis of the key players on novel technology.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to the region's increasing healthcare costs and population, government initiatives to improve the healthcare sector, and rising demand for iron-deficiency anemia therapy.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Iron-Deficiency Anemia Therapy Market Share Analysis

The iron-deficiency anemia therapy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to iron-deficiency anemia therapy market.

Some of the major players operating in the iron-deficiency anemia therapy market are:

  • Fresenius SE & Co. KGaA (Germany)
  • Sanofi (France)
  • Pfizer Inc. (U.S.)
  • GSK plc (U.K.)
  • Novartis AG (Switzerland)
  • AbbVie Inc. (U.S.)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (U.S.)
  • Teva Pharmaceutical Industries Ltd.(Ireland)
  • Lupin (India)
  • ViforPharma Ltd. (Switzerland)
  • AMAG Pharmaceuticals (U.S.)
  • Akebia Therapeutics, INC. (U.S.)
  • CHO-A Pharmaceutical CO., LTD. (South Korea)
  • Orion Corporation (Finland)
  • Pharmacosmos A/S (Denmark)
  • Shield Therapeutics (U.K.)
  • Advanz Pharmaceutical (U.K.)
  • Alkem Labs (India)
  • Zydus Cadila (India)
  • Hikma Pharmaceuticals PLC (U.K.)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The iron-deficiency anemia therapy market size will be worth USD 13,208.89 million by 2030.
The growth rate of the iron-deficiency anemia therapy market is 17.2% in the forecast period by 2030.
Therapy, therapy areas, population, end-users, and distribution channels are the factors on which the iron-deficiency anemia therapy market research is based.
Major companies in the iron-deficiency anemia therapy market are Fresenius SE & Co. KGaA (Germany), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AbbVie Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Ireland), Lupin (India), ViforPharma Ltd. (Switzerland), AMAG Pharmaceuticals (U.S.), Akebia Therapeutics, INC. (U.S.), CHO-A Pharmaceutical CO., LTD. (South Korea), Orion Corporation (Finland), Pharmacosmos A/S (Denmark), Shield Therapeutics (U.K.), Advanz Pharmaceutical (U.K.), Alkem Labs (India), Zydus Cadila (India), Hikma Pharmaceuticals PLC (U.K.)
Increasing prevalence of iron deficiency anemia (IDA) will bolster the market growth & growing research and clinical activities are the growth drivers of the iron-deficiency anemia therapy market.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials